据证券之星公开数据整理，近期羚锐制药(600285)发布2025年中报。截至本报告期末，公司营业总收入 20.99亿元，同比上升10.14%，归母净利润4.74亿元，同比上升14.85%。按单季度数据看，第二季度营 业总收入10.78亿元，同比上升8.17%，第二季度归母净利润2.58亿元，同比上升15.68%。本报告期羚锐 制药盈利能力上升，毛利率同比增幅6.95%，净利率同比增幅4.59%。 本次财报公布的各项数据指标表现尚佳。其中，毛利率81.33%，同比增6.95%，净利率22.67%，同比增 4.59%，销售费用、管理费用、财务费用总计10.97亿元，三费占营收比52.25%，同比增7.55%，每股净 资产5.41元，同比增13.44%，每股经营性现金流0.63元，同比增22.37%，每股收益0.84元，同比增 14.21% 证券之星价投圈财报分析工具显示： 财报体检工具显示： 建议关注公司现金流状况(货币资金/流动负债仅为26.05%) 分析师工具显示：证券研究员普遍预期2025年业绩在8.37亿元，每股收益均值在1.48元。 该公司被1位明星基金经理持有，持有该公司的最受关注的基金经理是易方达基 ...

Core Insights - Ares Management reported a revenue of $1.05 billion for the quarter ended June 2025, reflecting a year-over-year increase of 33.3% [1] - The earnings per share (EPS) for the quarter was $1.03, up from $0.99 in the same quarter last year, although it fell short of the consensus estimate of $1.11, resulting in an EPS surprise of -7.21% [1] Financial Performance - The reported revenue exceeded the Zacks Consensus Estimate of $1.03 billion by 1.41% [1] - The total Assets Under Management (AUM) reached $572.4 billion, surpassing the average estimate of $565.56 billion [4] - Fee-related performance revenues were reported at $16.7 million, below the average estimate of $18.1 million, marking a year-over-year decline of 22.6% [4] - Management fees amounted to $900.29 million, slightly below the average estimate of $913.48 million, but represented a 24% increase year-over-year [4] - Other fees saw a significant increase to $76.12 million, compared to the estimated $35.92 million, reflecting a year-over-year growth of 229.9% [4] Segment Performance - Realized income from the Secondaries Group was $48.72 million, exceeding the average estimate of $40.43 million, with a year-over-year increase of 53.8% [4] - Realized income from the Credit Group was $435.49 million, slightly below the estimate of $475.85 million, with a year-over-year growth of 6.8% [4] - Realized income from the Real Assets Group was reported at $97.65 million, below the average estimate of $109.73 million, but showed a substantial year-over-year increase of 131.3% [4] - Realized income from the Private Equity Group was $12.86 million, below the estimate of $17.95 million, with a year-over-year increase of 24.7% [4] Stock Performance - Ares Management shares returned +4.3% over the past month, outperforming the Zacks S&P 500 composite's +2.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]